Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last4,161 to 4,180 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Placebo + Prednisone 5 mg vs Orteronel 400 mg + Prednisone 5 mg: Number of Participants With Abnormal Clinically Significant Electrocardiogram (ECG) Findings | 130 of 770 163 of 784 | -3.9 points -7.8 to -0.0 | 1,554 | NCT01193244 Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer |
| Placebo + Prednisone 5 mg vs Orteronel 400 mg + Prednisone 5 mg: serious adverse events | 321 of 770 380 of 784 | -6.8 points -11.7 to -1.8 | 1,554 | NCT01193244 Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer |
| Antibiotics Therapy Arm vs Appendectomy Arm: Rates of Participants With Appendiceal Cancer | 4 of 776 6 of 776 | -0.3 points -1.2 to 0.6 | 1,552 | NCT02800785 The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) Trial |
| Standard Implementation Plus Health Coaching vs Standard Implementation Plus Health Coaching and Practice Facilitation: Reach-2 | 6 of 296 8 of 1,256 | 1.4 points 0.1 to 3.7 | 1,552 | NCT04907045 An Initial Study of the Implementation of Digital Therapeutics for Substance Use Disorders in Primary Care |
| Standard Implementation Plus Health Coaching vs Standard Implementation Plus Health Coaching and Practice Facilitation: Reach of the Digital Therapeutic to Patients in the Primary Care Clinic | 1 of 296 4 of 1,256 | 0.0 points -0.6 to 1.6 | 1,552 | NCT04907045 An Initial Study of the Implementation of Digital Therapeutics for Substance Use Disorders in Primary Care |
| Standard Implementation Plus Health Coaching vs Standard Implementation Plus Health Coaching and Practice Facilitation: Reach-3 | 1 of 296 6 of 1,256 | -0.1 points -0.8 to 1.4 | 1,552 | NCT04907045 An Initial Study of the Implementation of Digital Therapeutics for Substance Use Disorders in Primary Care |
| Linagliptin vs Glimepiride: serious adverse events | 135 of 776 162 of 775 | -3.5 points -7.4 to 0.4 | 1,551 | NCT00622284 Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes |
| Methoxy Polyethylene Glycol-epoetin Beta (Predialysis) vs Methoxy Polyethylene Glycol-epoetin Beta (Hemodialysis): serious adverse events | 7 of 346 67 of 1,201 | -3.6 points -5.3 to -1.2 | 1,547 | NCT01051323 An Observational Study of Mircera (Methoxy Polyethylene Glycol-epoetin Beta) in Patients With Renal Anemia |
| EEG Guided vs Usual Care: ICU Admission | 17 of 773 15 of 774 | 0.3 points -1.2 to 1.8 | 1,547 | NCT03330236 EEG - Guided Anesthetic Care and Postoperative Delirium |
| EEG Guided vs Usual Care: Number of Participants With Postoperative Delirium | 8 of 773 9 of 774 | -0.1 points -1.3 to 1.0 | 1,547 | NCT03330236 EEG - Guided Anesthetic Care and Postoperative Delirium |
| EEG Guided vs Usual Care: Emergence Delirium | 91 of 773 102 of 774 | -1.4 points -4.7 to 1.9 | 1,547 | NCT03330236 EEG - Guided Anesthetic Care and Postoperative Delirium |
| Empaglifozin 25 mg vs Glimepiride: The Occurrence of Confirmed Hypoglycaemic Events During 52 Weeks of Treatment. | 12 of 765 159 of 780 | -18.8 points -21.9 to -15.9 | 1,545 | NCT01167881 Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes |
| Empaglifozin 25 mg vs Glimepiride: The Occurrence of Confirmed Hypoglycaemic Events During 104 Weeks of Treatment. | 19 of 765 189 of 780 | -21.7 points -25.0 to -18.6 | 1,545 | NCT01167881 Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes |
| Empa 25mg vs Glimepiride: serious adverse events | 161 of 765 153 of 780 | 1.4 points -2.6 to 5.4 | 1,545 | NCT01167881 Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes |
| Fluid Restriction Group vs Standard-care: 90-day Mortality | 323 of 764 329 of 781 | 0.2 points -4.8 to 5.1 | 1,545 | NCT03668236 The Conservative vs. Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care Trial |
| Fluid Restriction Group vs Standard-care: deaths from any cause | 385 of 764 383 of 781 | 1.4 points -3.6 to 6.3 | 1,545 | NCT03668236 The Conservative vs. Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care Trial |
| Intervention Group vs Delay Results Group: Depression Response | 242 of 754 216 of 787 | 4.6 points 0.1 to 9.2 | 1,541 | NCT03170362 PRIME Care (PRecision Medicine In MEntal Health Care) |
| Intervention Group vs Delay Results Group: Depression Remission | 130 of 754 126 of 787 | 1.2 points -2.5 to 5.0 | 1,541 | NCT03170362 PRIME Care (PRecision Medicine In MEntal Health Care) |
| EEG Guided vs Usual Care: Non-delirium Complications | 175 of 768 193 of 773 | -2.2 points -6.4 to 2.1 | 1,541 | NCT03330236 EEG - Guided Anesthetic Care and Postoperative Delirium |
| Restrictive Fluids vs Liberal Fluids: Death From Any Cause at Any Location by Day 90 | 172 of 768 169 of 773 | 0.5 points -3.6 to 4.7 | 1,541 | NCT03434028 Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis |
Code
curl "https://conductscience.org/api/comparisons/v1?page=209"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=209
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT01193244-cd2ed095",
"title": "Placebo + Prednisone 5 mg vs Orteronel 400 mg + Prednisone 5 mg: Number of Participants With Abnormal Clinically Significant Electrocardiogram (ECG) Findings",
"summary": "130 of 770 against 163 of 784; risk difference -3.9 points, 95% interval -7.8 to -0.0; NCT01193244, Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer",
"record": "/library/comparisons/NCT01193244-cd2ed095",
"nct_id": "NCT01193244",
"kind": "outcome",
"participants": 1554,
"risk_difference": {
"value": -0.039076994434137285,
"lower": -0.07784445318261685,
"upper": -0.00015173915671862215
},
"group_1": "130 of 770",
"group_2": "163 of 784",
"difference": "-3.9 points",
"interval": "-7.8 to -0.0",
"trial_title": "Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer"
},
{
"id": "NCT01193244-sae",
"title": "Placebo + Prednisone 5 mg vs Orteronel 400 mg + Prednisone 5 mg: serious adverse events",
"summary": "321 of 770 against 380 of 784; risk difference -6.8 points, 95% interval -11.7 to -1.8; NCT01193244, Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer",
"record": "/library/comparisons/NCT01193244-sae",
"nct_id": "NCT01193244",
"kind": "serious-adverse-events",
"participants": 1554,
"risk_difference": {
"value": -0.06781076066790354,
"lower": -0.11681558999114995,
"upper": -0.018329532646512978
},
"group_1": "321 of 770",
"group_2": "380 of 784",
"difference": "-6.8 points",
"interval": "-11.7 to -1.8",
"trial_title": "Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=210",
"request_id": "ON7cr6ZPWnJDr4l6"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant